Drug Trial Radar · NCT04440982
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
98
Actual
Start
Sep 1, 2020
Primary completion
Nov 30, 2023
Study completion Feb 29, 2024
Sponsor
- Lead sponsor
- Lumicell, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, randomized, clinical trial evaluating patients undergoing breast conserving surgery using the LUM Imaging System.
Conditions
- Breast Cancer
- Neoadjuvant Therapy
Interventions
LUM015Drug
LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
Lum Imaging SystemDevice
UM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development and validation of tumor detection algorithms in breast cancer patients receiving neoadjuvant therapyTime frame: 1 month
- Number of patients with reported adverse eventsTime frame: 14 days
- Reduction in residual tumorTime frame: 3 months
- Report on patient reported outcomes and patient preference informationTime frame: 12 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Stanford Hospital and Clinics
Palo Alto, California
Morton Plant Mease Health Care Oncology Research
Clearwater, Florida
Massachusetts General Hospital
Boston, Massachusetts
Duke Cancer Center
Durham, North Carolina
Novant Health Cancer Center
Winston-Salem, North Carolina
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.